BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31771594)

  • 21. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
    Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
    J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
    Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies.
    Xu L; Benoy I; Cuschieri K; Poljak M; Bonde J; Arbyn M
    Expert Rev Mol Diagn; 2019 Jun; 19(6):543-551. PubMed ID: 31035813
    [No Abstract]   [Full Text] [Related]  

  • 24. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Racial and Ethnic Differences in Acceptability of Urine and Cervico-Vaginal Sample Self-Collection for HPV-Based Cervical Cancer Screening.
    Rohner E; McGuire FH; Liu Y; Li Q; Miele K; Desai SA; Schmitt JW; Knittel A; Nelson JAE; Edelman C; Sivaraman V; Baker A; Romocki LS; Rahangdale L; Smith JS
    J Womens Health (Larchmt); 2020 Jul; 29(7):971-979. PubMed ID: 32212991
    [No Abstract]   [Full Text] [Related]  

  • 26. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
    Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions.
    King J; Flores YN; Meneses-León J; Hernández-Salazar S; Robles-Rivera K; Rivera-Paredez B; León-Maldonado L; Hernández-López R; Torres-Ibarra L; Lazcano-Ponce E; Salmerón J
    Cancer Prev Res (Phila); 2023 Dec; 16(12):681-687. PubMed ID: 37788346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
    Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
    Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
    Arbyn M; Smith SB; Temin S; Sultana F; Castle P;
    BMJ; 2018 Dec; 363():k4823. PubMed ID: 30518635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus infection and cervical dysplasia in HIV-positive women: potential role of the vaginal microbiota.
    van de Wijgert JHHM; Gill AC; Chikandiwa A; Verwijs MC; Kelly HA; Omar T; Delany-Moretlwe S; Segondy M; Francis S; Darby AC; Mayaud P;
    AIDS; 2020 Jan; 34(1):115-125. PubMed ID: 31567164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis.
    van der Marel J; van Baars R; Quint WG; Berkhof J; del Pino M; Torné A; Ordi J; Wentzensen N; Schiffman M; van de Sandt MM; Lindeman J; Jenkins D; Helmerhorst TJ; Verheijen RH; ter Harmsel B; Alonso I
    BJOG; 2014 Aug; 121(9):1117-26. PubMed ID: 24494663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
    Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ
    Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer.
    Verhoef VM; Heideman DA; van Kemenade FJ; Rozendaal L; Bosgraaf RP; Hesselink AT; Bekkers RL; Massuger LF; Steenbergen RD; Snijders PJ; Berkhof J; Meijer CJ
    Gynecol Oncol; 2014 Oct; 135(1):58-63. PubMed ID: 25111387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Evaluation of INNO-LiPA HPV Genotyping
    Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.